Myeloma-Developing Regimens Using Genomics (MyDRUG) (Genomics Guided Multi-arm Trial of Targeted Agents Alone or in Combination With a Backbone Regimen)
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 19 Dec 2018
At a glance
- Drugs Abemaciclib (Primary) ; Cobimetinib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Enasidenib (Primary) ; Erdafitinib (Primary) ; Ixazomib (Primary) ; Pomalidomide (Primary) ; Venetoclax (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms MyDRUG
- 11 Dec 2018 Planned End Date changed from 10 Dec 2023 to 10 Feb 2024.
- 11 Dec 2018 Planned primary completion date changed from 10 Dec 2021 to 10 Feb 2022.
- 11 Dec 2018 Planned initiation date changed from 10 Dec 2018 to 10 Feb 2019.